Genentech/OSI Touting Tarceva Pancreatic Cancer Overall Survival Benefit

Genentech and marketing partner OSI are highlighting the overall survival benefit of combination use with Tarceva over gemcitabine (Lilly's Gemzar) plus placebo for treatment of advanced pancreatic cancer